Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...